Related Experiment Videos
[5-aminosalicylic acid and chronic inflammatory bowel diseases in children]
1Dr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Stuttgart.
Insights
5-Aminosalicylate (mesalazine; 5-AS) is effective for inflammatory bowel disease in adults. Limited pediatric data exist, but its safety and pharmacokinetics support use in children.
Area of Science:
- Pharmacology
- Gastroenterology
Context:
- Inflammatory bowel disease (IBD) management
- Limited pediatric data for 5-aminosalicylate (mesalazine; 5-AS)
Purpose:
- Review available pediatric data for 5-AS
- Assess 5-AS suitability for pediatric IBD patients
Summary:
- 5-Aminosalicylate (mesalazine; 5-AS), the active metabolite of sulfasalazine, is a proven IBD therapy in adults.
- Pharmacokinetic properties of 5-AS are consistent across age groups.
- 5-AS demonstrates a wide safety margin, suggesting potential for pediatric use.
Impact:
- Encourages further clinical studies of 5-AS in children.
- Supports the expanded use of 5-AS for pediatric inflammatory bowel disease.
Abstract:
5-Aminosalicylate (mesalazine; 5-AS) represents a new therapeutic strategy in chronic inflammatory bowel disease. The drug (active metabolite of sulfasalazine) has proven its clinical efficacy and safety in numerous controlled studies in adults. However only limited data are available for the pediatric population. This brief review summarises the published spares information on this promising agent. As pharmacokinetic properties of 5-AS are age-independent and since 5-AS has a wide margin of safety clinical studies and use of this drug should be encouraged also in children.